Tag Archive for: Canada

Alvotech said on Thursday it has reached settlement agreements with Johnson & Johnson for launching a biosimilar of the pharmaceutical giant’s blockbuster psoriasis drug Stelara in Japan, Canada, and Europe this year.

Biogen has disclosed in a Wednesday Securities and Exchange Commission filing that it has been served a subpoena by the U.S. Department of Justice, which is seeking more information regarding the company’s overseas operations.

The CEOs of Bristol Myers Squibb, Johnson & Johnson and Merck testified Thursday before the Senate health committee, defending the high U.S. prices that Americans pay for prescription drugs compared to other countries based on patient value and the need to fund innovation and R&D costs.  

The regulator’s Complete Response Letter flagged issues with the new formulation of tesamorelin’s chemistry, manufacturing and controls and sought more information about its immunogenicity risk.

At the beginning of January, the FDA announced that it was authorizing Florida’s Agency for Health Care Administration to import certain prescription drugs from Canada. Leslie Isenegger, practice leader, corporate pricing and public affairs at Real Chemistry, answers some key questions about the implications the program could have on the pharma industry.

Today the company announced that Canada’s health regulator approved its gene therapy for the treatment of a rare inherited bleeding disorder called hemophilia B ahead of a U.S. decision.

BioVaxys Technology Corp. announced that it has executed a non-binding Letter of Intent to acquire the core platform technology and entire immunotherapeutics intellectual property portfolio formerly owned by an unnamed biotechnology company and now held by the unnamed company’s former secured creditor.

Today the company said its experimental drug to treat major depressive disorder (MDD) had failed to significantly reduce the severity of the condition in a mid-stage study.

Canada has detected its first case of coronavirus infection from the highly mutated BA.2.86 variant of Omicron in a person in British Columbia who had not traveled outside the Pacific province, health officials said on Tuesday.

The biotech will supply Canada with fewer doses of its coronavirus vaccine while reaching a financial agreement for the forfeiting of certain doses previously scheduled for delivery.